Ironwood Pharmaceuticals Forecast, price target & analysts
Ironwood Pharmaceuticals Target price 2025 - Analyst rating & recommendation
Ironwood Pharmaceuticals Classifications & Recommendation:
Ironwood Pharmaceuticals Price Target
| Target Price | $1.02 |
| Price | $2.05 |
| Deviation |
50.24%
register free of charge
|
| Number of Estimates | 6 |
|
6 Analysts have issued a price target Ironwood Pharmaceuticals 2026 .
The average Ironwood Pharmaceuticals target price is $1.02.
This is
50.24%
register free of charge
$1.16
43.66%
register free of charge
$0.71
65.51%
register free of charge
|
|
| A rating was issued by 10 analysts: 0 Analysts recommend Ironwood Pharmaceuticals to buy, 7 to hold and 3 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the Ironwood Pharmaceuticals stock has an average upside potential 2026 of
50.24%
register free of charge
|
Sales and Margin forecast 2025, 2026 to 2032
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Revenue Million $ | 351.41 | 283.36 |
| 20.63% | 19.36% | |
| EBITDA Margin | 27.81% | 39.31% |
| 27.53% | 41.35% | |
| Net Margin | 0.25% | 13.93% |
| 100.11% | 5,462.66% |
7 Analysts have issued a sales forecast Ironwood Pharmaceuticals 2025 . The average Ironwood Pharmaceuticals sales estimate is
This results in the following potential growth metrics:
5 Analysts have issued an Ironwood Pharmaceuticals EBITDA forecast 2025. The average Ironwood Pharmaceuticals EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
7 Ironwood Pharmaceuticals Analysts have issued a net profit forecast 2025. The average Ironwood Pharmaceuticals net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2032
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Earnings Per Share $ | 0.01 | 0.24 |
| 100.16% | 2,300.00% | |
| P/E | 8.43 | |
| EV/Sales | 2.91 |
7 Analysts have issued a Ironwood Pharmaceuticals forecast for earnings per share. The average Ironwood Pharmaceuticals EPS is
This results in the following potential growth metrics and future valuations:
Ironwood Pharmaceuticals...
Current Ironwood Pharmaceuticals Upgrades & Downgrades
| Analyst | Rating | Action | Date |
|---|---|---|---|
| Jefferies |
Locked
➜
Locked
|
Locked | Apr 15 2025 |
| Wells Fargo |
Locked
➜
Locked
|
Locked | Apr 15 2025 |
| Leerink Partners |
Locked
➜
Locked
|
Locked | Apr 14 2025 |
| JMP Securities |
Locked
➜
Locked
|
Locked | Jan 30 2025 |
| Craig-Hallum |
Locked
➜
Locked
|
Locked | Jan 22 2025 |
| Leerink Partners |
Locked
➜
Locked
|
Locked | Sep 09 2024 |
| Analyst Rating | Date |
|---|---|
|
Locked
Jefferies:
Locked
➜
Locked
|
Apr 15 2025 |
|
Locked
Wells Fargo:
Locked
➜
Locked
|
Apr 15 2025 |
|
Locked
Leerink Partners:
Locked
➜
Locked
|
Apr 14 2025 |
|
Locked
JMP Securities:
Locked
➜
Locked
|
Jan 30 2025 |
|
Locked
Craig-Hallum:
Locked
➜
Locked
|
Jan 22 2025 |
|
Locked
Leerink Partners:
Locked
➜
Locked
|
Sep 09 2024 |
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
